Considering the overexpression of IL-4/IL-13 and their respective receptors in cancers, their stimulative roles for tumor progression [53,60,132] coupled with the property that cytokines bind to respective receptors with high efficacy and specificity, it is reasonable to design novel therapeutic approaches targeting the IL-4/13 axis. The gene discussed is IL13; the disease is neoplasm.